These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis. Michel S; Bigdeli AK; Hagl C; Meiser B; Kaczmarek I Exp Clin Transplant; 2013 Oct; 11(5):429-34. PubMed ID: 24128136 [TBL] [Abstract][Full Text] [Related]
8. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
9. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. Taylor DO; Barr ML; Radovancevic B; Renlund DG; Mentzer RM; Smart FW; Tolman DE; Frazier OH; Young JB; VanVeldhuisen P J Heart Lung Transplant; 1999 Apr; 18(4):336-45. PubMed ID: 10226898 [TBL] [Abstract][Full Text] [Related]
10. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
11. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529 [TBL] [Abstract][Full Text] [Related]
12. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? Groetzner J; Meiser BM; Schirmer J; Koglin J; vScheidt W; Klauss V; Cremer P; Reichenspurner H; Reichart B Transplant Proc; 2001; 33(1-2):1461-4. PubMed ID: 11267373 [No Abstract] [Full Text] [Related]
13. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019 [TBL] [Abstract][Full Text] [Related]
16. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients. Kim SJ; Prasad GV; Huang M; Nash MM; Famure O; Park J; Thenganatt MA; Chowdhury N; Cole EH; Fenton SS; Cattran DC; Zaltzman JS; Cardella CJ Transplantation; 2006 Oct; 82(7):924-30. PubMed ID: 17038908 [TBL] [Abstract][Full Text] [Related]
17. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. Jacobson PA; Schladt D; Israni A; Oetting WS; Lin YC; Leduc R; Guan W; Lamba V; Matas AJ; Transplantation; 2012 Mar; 93(6):624-31. PubMed ID: 22334041 [TBL] [Abstract][Full Text] [Related]
19. Kidney function in cyclosporine-treated pediatric heart transplant recipients. Laine J; Jalanko H; Leijala M; Sairanen H; Holmberg C J Heart Lung Transplant; 1997 Dec; 16(12):1217-24. PubMed ID: 9436133 [TBL] [Abstract][Full Text] [Related]
20. Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation. Helmschrott M; Rivinius R; Ruhparwar A; Schmack B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Ehlermann P; Bruckner T; Katus HA; Doesch AO Drug Des Devel Ther; 2015; 9():1217-24. PubMed ID: 25759566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]